Indeed, evidence supporting TWEAK/Fn14-mediated pathological mechanisms in contexts of acute kidney injury and chronic kidney diseases is substantial and clinical targeting of TWEAK is ongoing in lupus nephritis (5). This evidence concerns the gene TNFSF12 and chronic kidney disease.